Inventiva (IVEVF) EBITDA Margin (2020 - 2021)
Inventiva (IVEVF) posted EBITDA Margin of 21021.54% for Q2 2021, down 56.47% on a QoQ basis from 13435.14% in Q1 2021, and down 904857.0% year-over-year from N/an in Q2 2020.
Powered by 
Analysis
Inventiva (IVEVF) EBITDA Margin (2020 - 2021) Analysis & Trends
Inventiva has reported EBITDA Margin for 2 years, with the latest figure at 21021.54% in Q2 2021.
- On a quarterly basis, EBITDA Margin fell 904857.0% year-over-year to 21021.54% in Q2 2021; TTM through Jun 2021 was 21339.07%, a N/A change from a year earlier, with the FY2025 full-year figure at 3145.51%, down 208486.0% from the prior year.
- EBITDA Margin was 21021.54% for Q2 2021 at Inventiva, down from 13435.14% in the prior quarter.
- The five-year high for EBITDA Margin was 7821.84% in Q1 2020, with the low at 21021.54% in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.04 Bn | 624.28 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 440.25 Bn | 433.68 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 365.65 Bn | 358.51 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 266.64 Bn | 258.95 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 44.19 Bn | 44.19 Bn | - | - |
| 8 | Incyte | 25.29 Bn | 20.75 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 42.23% |
| 10 | Inventiva | 693.72 Mn | 693.72 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -21,021.54% |
| Mar 31, 2021 | -13,435.14% |
| Jun 30, 2020 | -11,972.97% |
| Mar 31, 2020 | -7,821.84% |